Difei Yang
Stock Analyst at Mizuho
(1.97)
# 2,933
Out of 4,670 analysts
41
Total ratings
30.56%
Success rate
7.25%
Average return
Main Sectors:
Stocks Rated by Difei Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Downgrades: Neutral | $6 → $2 | $1.88 | +6.38% | 4 | Mar 31, 2022 | |
| BLUE bluebird bio | Maintains: Buy | $29 → $23 | $0.35 | +6,469.55% | 3 | Sep 22, 2021 | |
| NVCR NovoCure | Maintains: Neutral | $229 → $200 | $17.73 | +1,028.03% | 6 | Jul 30, 2021 | |
| CASI CASI Pharmaceuticals | Initiates: Buy | $38 | $5.10 | +645.10% | 1 | Apr 26, 2021 | |
| FGEN FibroGen | Downgrades: Neutral | $29 | $0.40 | +7,234.34% | 4 | Apr 7, 2021 | |
| QURE uniQure | Upgrades: Buy | $52 | $5.78 | +799.65% | 4 | Apr 1, 2021 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $158 → $160 | $114.23 | +40.07% | 2 | Feb 26, 2021 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $18 → $14 | $3.09 | +353.07% | 4 | Apr 23, 2020 | |
| RVNC Revance Therapeutics | Maintains: Buy | $39 → $35 | $3.73 | +838.34% | 3 | Apr 1, 2020 | |
| NKTR Nektar Therapeutics | Upgrades: Buy | $21 → $35 | $1.05 | +3,233.33% | 4 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $52 → $20 | $0.33 | +6,053.85% | 2 | Feb 27, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.35 | - | 2 | Aug 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $9.59 | +191.97% | 1 | Feb 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $1.07 | +2,516.82% | 1 | Sep 27, 2017 |
Akebia Therapeutics
Mar 31, 2022
Downgrades: Neutral
Price Target: $6 → $2
Current: $1.88
Upside: +6.38%
bluebird bio
Sep 22, 2021
Maintains: Buy
Price Target: $29 → $23
Current: $0.35
Upside: +6,469.55%
NovoCure
Jul 30, 2021
Maintains: Neutral
Price Target: $229 → $200
Current: $17.73
Upside: +1,028.03%
CASI Pharmaceuticals
Apr 26, 2021
Initiates: Buy
Price Target: $38
Current: $5.10
Upside: +645.10%
FibroGen
Apr 7, 2021
Downgrades: Neutral
Price Target: $29
Current: $0.40
Upside: +7,234.34%
uniQure
Apr 1, 2021
Upgrades: Buy
Price Target: $52
Current: $5.78
Upside: +799.65%
Sarepta Therapeutics
Feb 26, 2021
Maintains: Buy
Price Target: $158 → $160
Current: $114.23
Upside: +40.07%
Xeris Biopharma Holdings
Apr 23, 2020
Maintains: Buy
Price Target: $18 → $14
Current: $3.09
Upside: +353.07%
Revance Therapeutics
Apr 1, 2020
Maintains: Buy
Price Target: $39 → $35
Current: $3.73
Upside: +838.34%
Nektar Therapeutics
Feb 3, 2020
Upgrades: Buy
Price Target: $21 → $35
Current: $1.05
Upside: +3,233.33%
Feb 27, 2019
Downgrades: Neutral
Price Target: $52 → $20
Current: $0.33
Upside: +6,053.85%
Aug 8, 2018
Upgrades: Buy
Price Target: n/a
Current: $2.35
Upside: -
Feb 13, 2018
Initiates: Neutral
Price Target: $28
Current: $9.59
Upside: +191.97%
Sep 27, 2017
Initiates: Buy
Price Target: $28
Current: $1.07
Upside: +2,516.82%